SynthesisPloS one2024
Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
Synthesis in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Evaluation of the Systemic Immune-Inflammation Index, Neutrophil-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio in Patients Diagnosed with Lung Cancer by Bronchoscopy in Relation to Disease Stage and PET/CT SUVmax.World journal of nuclear medicine · 2026Article
- Prognostic Impact of the Systemic Immune-Inflammation Index According to Concurrent Chemotherapy Backbone in Stage III Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Clinical Value of the Systemic Immune Inflammation Index and PD-L1 Expression in Advanced NSCLC Treated with Pembrolizumab: Real-World Preliminary Study.Oncology research · 2026Article
- Risk-adapted use of thoracic radiotherapy in stage IV non-small cell lung cancer: a multicenter prognostic model study.Frontiers in oncology · 2026Article
- Clinical inflammatory shifts and peripheral flow-cytometry immune modules across benign pulmonary nodules, adenocarcinoma-spectrum nodules, and overt lung cancer.Frontiers in immunology · 2026Article
- Association of systemic immune-inflammation index with all-cause mortality in lung cancer patients undergoing radiotherapy: a retrospective cohort study.Frontiers in oncology · 2026Article
- Systemic immune-inflammation index prior to postoperative radiotherapy as a tool for outcome prediction in thymic epithelial tumors.Radiation oncology journal · 2025Article
- Retrospective study on the prognostic prediction of inflammatory markers and the C-reactive protein/albumin ratio in first-line immunotherapy for advanced HER2 negative gastric cancer patients.Translational cancer research · 2025Article
- Impact of pneumonitis from radiotherapy combined with immune checkpoint inhibitors therapy on tumor progression and survival in patients with non-small cell lung cancer.Frontiers in immunology · 2025Article
- Prognostic role of inflammatory and tumor biomarkers in hilar cholangiocarcinoma patients receiving postoperative adjuvant therapy.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the association between the systemic immune-inflammation index (SII) score and prognosis in immune checkpoint inhibitor (ICI)-treated patients with lung cancer.
methodsPubMed, EMBASE, Web of Science, and CNKI databases were searched up to August 1, 2024. Progression-free survival (PFS) and overall survival (OS) were the primary outcomes queried. Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined, and subgroup analysis was based on pathological type [non-small cell lung cancer (NSCLC) vs. small-cell lung cancer (SCLC)], lines of ICIs (first-line vs. second- or further-line), and combinations of other therapies (yes vs. no).
resultsTwenty retrospective studies with 2424 participants were included. The pooled results demonstrated that an elevated SII was associated with poorer PFS (HR = 1.82, 95% CI: 1.49-2.21; P < 0.001) and OS (HR = 2.31, 95% CI: 1.73-3.09; P < 0.001) in lung cancer patients receiving ICIs. Subgroup analysis stratified by pathological type, lines of ICIs and combinations of other therapies for PFS and OS further revealed the predictive role of the SII in ICI-treated lung cancer patients.
conclusionBased on current evidence the SII is significantly related to prognosis and could serve as a reliable prognostic indicator in lung cancer patients receiving ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.